IFP Advisors Inc raised its position in TESARO, Inc. (NASDAQ:TSRO) by 6.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,471 shares of the biopharmaceutical company’s stock after buying an additional 265 shares during the period. IFP Advisors Inc’s holdings in TESARO were worth $625,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. Vident Investment Advisory LLC acquired a new stake in TESARO during the first quarter worth approximately $351,000. Meeder Asset Management Inc. acquired a new stake in TESARO during the first quarter worth approximately $177,000. Fox Run Management L.L.C. acquired a new stake in TESARO during the second quarter worth approximately $224,000. World Asset Management Inc acquired a new stake in TESARO during the second quarter worth approximately $227,000. Finally, Private Capital Advisors Inc. acquired a new stake in TESARO during the second quarter worth approximately $232,000.
Shares of TESARO, Inc. (NASDAQ:TSRO) opened at 111.85 on Friday. TESARO, Inc. has a 52-week low of $83.26 and a 52-week high of $192.94. The company’s market capitalization is $6.06 billion. The company has a 50-day moving average of $130.46 and a 200 day moving average of $149.15.
TESARO (NASDAQ:TSRO) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) EPS for the quarter, missing analysts’ consensus estimates of ($2.52) by $0.30. The company had revenue of $29.50 million during the quarter, compared to analyst estimates of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The company’s revenue for the quarter was down 17.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.28) earnings per share. Analysts predict that TESARO, Inc. will post ($8.45) earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “IFP Advisors Inc Has $625,000 Stake in TESARO, Inc. (NASDAQ:TSRO)” was published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.com-unik.info/2017/08/12/ifp-advisors-inc-has-625000-stake-in-tesaro-inc-nasdaqtsro.html.
A number of research firms have commented on TSRO. Robert W. Baird reaffirmed a “neutral” rating and set a $140.00 target price (down previously from $155.00) on shares of TESARO in a report on Thursday. Janney Montgomery Scott set a $139.00 target price on shares of TESARO and gave the stock a “hold” rating in a report on Saturday, June 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $183.00 target price on shares of TESARO in a report on Thursday. Cowen and Company set a $145.00 target price on shares of TESARO and gave the stock a “hold” rating in a report on Saturday, June 10th. Finally, ValuEngine raised shares of TESARO from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. One analyst has rated the stock with a sell rating, ten have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $176.35.
In other TESARO news, VP Edward C. English sold 8,500 shares of the firm’s stock in a transaction on Tuesday, June 6th. The shares were sold at an average price of $138.65, for a total value of $1,178,525.00. Following the completion of the sale, the vice president now directly owns 5,396 shares in the company, valued at $748,155.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 40.50% of the company’s stock.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO, Inc. (NASDAQ:TSRO).
What are top analysts saying about TESARO Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TESARO Inc. and related companies.